HPLC Chiral Separation of Nebivolol Enantiomers on Cyralis AM Column

HPLC Chiral Method for Analysis of Nebivolol Enantiomers on Cyralis AM Column by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Nebivolol.

Nebivolol is a beta-blocker with the chemical formula C22H25F2NO4. It is an oral medication used to treat high blood pressure, but is not preferred to alternatives. Side effects of it include dizziness, fatigue, nausea, and headaches. You can find detailed UV spectra of Nebivolol and information about its various lambda maxima by visiting the following link.

This application describes a normal-phase chiral HPLC method for the separation of Nebivolol enantiomers using SIELC’s Cyralis AM chiral column. Cyralis AM is an amylose-based chiral stationary phase (CSP) designed for enantiomeric separations, optical purity testing, chiral impurity analysis, and stereoisomer characterization in pharmaceutical, chemical, agrochemical, and fine chemical applications.

Nebivolol can be retained and analyzed using the Cyralis AM stationary phase column. The analysis utilizes an isocratic method with a mobile phase consisting of Hexane, Ethanol, and DEA. Detection is performed using UV.

Condition

ColumnCyralis AM, 4.6 x 100 mm, 5 µm, 100 A, normal phase
Mobile PhaseHexane/Ethanol/DEA
Flow Rate1.0 mL/min
DetectionUV 280 nm
Resolution2.06

Description

Class of Compoundsbeta-blockers
Analyzing CompoundsNebivolol

Application Column

Cyralis AM

Column Diameter: 4.6 mm
Column Length: 100 mm
Particle Size: 5 µm
Pore Size: 100 A
Column options: normal phase

Add to cart
Application Analytes:
Nebivolol
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.